Zoomed Image
  • Aprovasc 300/5mg Tablets 28's

Aprovasc 300/5mg Tablets 28's

kes3,370
Description
Irbesartan/amlodipine (Aprovasc®) is an angiotensin-receptor blocker/calcium-channel blocker fixed-dose single-pill combination, whose constituent drugs exert additive effects when coadministered. It is indicated in patients whose blood pressure is not adequately controlled on irbesartan or amlodipine monotherapy. Irbesartan and Amlodipine: The pharmacodynamic properties of each drug, Irbesartan and Amlodipine, provide an addition of antihypertensive effects when administered in combination against the effect observed with both components separately. Both the AT1 receptor blocker and the calcium channel antagonist lower blood pressure by reducing peripheral resistance, but blocking calcium flow and reducing vasoconstriction by angiotensin II are complementary mechanisms. Irbesartan: Mechanism of action: Irbesartan is a specific antagonist of angiotensin II receptors (AT1 subtype). Angiotensin II is an important component of the renin-angiotensin system, it participates in the pathophysiology of hypertension and in sodium homeostasis. Irbesartan does not require metabolic activation for its action. Irbesartan blocks the potent vasoconstriction and aldosterone secretion effects produced by angiotensin II, by selective antagonism of angiotensin II receptors (AT1 subtype) located in vascular smooth muscle cells and in the adrenal cortex. Irbesartan has no agonist activity at the AT1 receptor and has a much higher affinity (more than 8,500 times) for the AT1 receptor than for the AT2 receptor (a receptor that has not been shown to be associated with cardiovascular homeostasis). Irbesartan does not inhibit the enzymes that participate in the renin-angiotensin system, that is, the angiotensin-converting enzyme (ACE), nor does it affect other hormone receptors or ion channels that are involved in the cardiovascular regulation of blood pressure and in sodium homeostasis. AT1 receptor blockade caused by irbesartan disrupts the feedback loop within the renin-angiotensin system, resulting in increases in plasma renin and angiotensin II levels.
How to use
Follow exactly the instructions of Aprovasc ® given by your doctor. Ask your doctor or pharmacist if you have questions. The usual dose of Aprovasc ® is 1 tablet a day. It can be administered with or without food by mouth with a sufficient amount of liquid. You should try to take your daily dose at the same time each day. It is important that you continue taking Aprovasc ® until your doctor advises you otherwise.
Precautions
Due to the presence of both irbesartan and amlodipine, Aprovasc ® is contraindicated in: Hypersensitivity to both the active substances or any component of the formulation. Hypersensitivity to dihydropyridines. Cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal's angina). Pregnancy and lactation (see Warnings and Pregnancy and Lactation sections). -Do not co-administer Aprovasc ® with aliskiren-containing medicinaDue to the presence of both irbesartan and amlodipine, Aprovasc ® is contraindicated in: Hypersensitivity to both the active substances or any component of the formulation. Hypersensitivity to dihydropyridines. Cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal's angina). Pregnancy and lactation (see Warnings and Pregnancy and Lactation sections). -Do not co-administer Aprovasc ® with aliskiren-containing medicinal products in patients with diabetes or with moderate to severe renal insufficiency (glomerular filtration rate (IFG) <60 ml / min / 1.73 m 2 ). Do not co-administer Aprovasc ® with ACE inhibitors (angiotensin converting enzyme inhibitors) in patients with diabetic l products in patients with diabetes or with moderate to severe renal insufficiency (glomerular filtration rate (IFG) <60 ml / min / 1.73 m 2 ). Do not co-administer Aprovasc ® with ACE inhibitors (angiotensin converting enzyme inhibitors) in patients with diabetic nephropathy.